NEWS & EVENTS

ChatGPT Image 18 sept. 2025 à 11_16_23.png

Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan

Nov 11, 2025

Read Article

Swipe down to read more news

Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program

Oct 28, 2025

Read Article

Swipe down to read more news

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

Apr 22, 2025

Read Article

Swipe down to read more news

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

Jan 24, 2024

Read Article

Swipe down to read more news

Emercell NK-001 (OT-C001) project selected as part of France 2030 plan “Biotherapies and bioproduction of innovative therapies"

Jul 24, 2023

Read Article

Swipe down to read more news

Onward Therapeutics To Present at the Swiss Biotech Day 2023 on April 25, 2023

Apr 10, 2023

Read Article

Swipe down to read more news

Our affiliate Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

Sep 23, 2022

Read Article

Swipe down to read more news

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

Jun 20, 2022

Read Article

Swipe down to read more news

Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier

Jun 08, 2021

Read Article

Swipe down to read more news

Onward Therapeutics SA opened a wholly owned affiliate, Onward Therapeutics France SAS in Paris, France

May 04, 2021

Read Article

Swipe down to read more news

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

Feb 17, 2021

Read Article

Swipe down to read more news

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

Feb 16, 2021

Read Article

Swipe up to read more news

Nov 11, 2025

Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan

Oct 28, 2025

Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program

Apr 22, 2025

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

Jan 24, 2024

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

Jul 24, 2023

Emercell NK-001 (OT-C001) project selected as part of France 2030 plan “Biotherapies and bioproduction of innovative therapies"

Apr 10, 2023

Onward Therapeutics To Present at the Swiss Biotech Day 2023 on April 25, 2023

Sep 23, 2022

Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

Jun 20, 2022

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

Jun 08, 2021

Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier

May 04, 2021

Onward Therapeutics SA opened a wholly owned affiliate, Onward Therapeutics France SAS in Paris, France

Feb 17, 2021

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

Feb 16, 2021

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan

Nov 11, 2025

Read Article

Swipe down to read more news

Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program

Oct 28, 2025

Read Article

Swipe down to read more news

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

Apr 22, 2025

Read Article

Swipe down to read more news

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

Jan 24, 2024

Read Article

Swipe down to read more news

Emercell NK-001 (OT-C001) project selected as part of France 2030 plan “Biotherapies and bioproduction of innovative therapies"

Jul 24, 2023

Read Article

Swipe down to read more news

Onward Therapeutics To Present at the Swiss Biotech Day 2023 on April 25, 2023

Apr 10, 2023

Read Article

Swipe down to read more news

Our affiliate Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

Sep 23, 2022

Read Article

Swipe down to read more news

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

Jun 20, 2022

Read Article

Swipe down to read more news

Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier

Jun 08, 2021

Read Article

Swipe down to read more news

Onward Therapeutics SA opened a wholly owned affiliate, Onward Therapeutics France SAS in Paris, France

May 04, 2021

Read Article

Swipe down to read more news

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

Feb 17, 2021

Read Article

Swipe down to read more news

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

Feb 16, 2021

Read Article